Compare Cassava Sciences Inc (FLNA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nomura Holdings Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 596× Cassava Sciences Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NMR | |
|---|---|---|
Market Cap | $47.75M | $28.46B |
Sector | Health | Financials |
52-Week High | $4.64 | $10.04 |
52-Week Low | $0.87 | $6.73 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Nomura Holdings (NMR) trades at $9.905, up 0.87% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.59, net income margin of 20.4%, and robust revenue growth to $1.66 trillion in 2025. Recent Q2 2026 earnings beat expectations, and news highlights momentum in wholesale and wealth management divisions.
Outlook remains positive due to earnings strength and undervaluation, but risks include volatile cash flows and rising debt-to-asset ratio. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
